Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-06-14 00:00:00 ET · period of report 2022-06-10 · accession 0000886163-22-000090 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-14 | 2022-06-10 | LGND | Korenberg Matthew E | EVP, CFO, Fin, Strategy | A - Grant | $0.00 | +8,062 | 52.4K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-10 | A | A | 8,062 | $0.00 | 52,368 | D | — | — |